XBiotech Inc.

XBIT

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001626878

SEC filings (opens in a new tab)

In the last 90 days, XBiotech Inc. insiders filed 1 open-market purchase and 0 sales; 36 institutions reported holding it in 13F filings for Q2 2026, worth $4.56M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 10, 2026: $60.1M
Insider buysLast 90 days, $711.3K in total: 1
Insider sellsOpen market, last 90 days: 0
13F holdersQ2 2026, +1 vs. previous quarter: 36
13F valueReported value at the end of Q2 2026: $4.56M
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: –; No comparable prior period
Net income, FY2025: -$45.5M; No comparable prior period
Free cash flow, FY2025: -$40.2M; No comparable prior period
Revenue, Q2 FY2026: –; No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 315.3K; Shares sold short
Change: +14.4K; +4.8% vs. previous
Days to cover: 2.64; At average daily volume

Superinvestors holding XBIT, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding XBIT at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by XBiotech Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Oct 28, 2026 (view filing)2:37 PM ET	Oct 26	2 days	Simard JohnDirector, 10% Owner	PPurchase	+368.5K	$1.93	+$711.3K	+9.6%4.19M after
Jan 5, 2024 (view filing)	Jan 3	2 days	Simard JohnChief Executive Officer	PPurchaseCommon Shares or Preferred Shares	+2.47M	$10,000,000.00	+$24.7T	–3.84M after	DerivativePrice outlier
Feb 15, 2022 (view filing)	Oct 15-18, 2021	123 daysLate	Simard JohnChief Executive Officer	SSale	−50.0K	$13.16	−$657.8K	−1.3%3.82M after	2 lots
Oct 15, 2021 (view filing)	Oct 7-14	8 daysLate	Simard JohnChief Executive Officer	SSale	−89.3K	$12.67	−$1.13M	−2.3%3.87M after	4 lots
Oct 6, 2021 (view filing)	Oct 4-6	2 days	Simard JohnChief Executive Officer	SSale	−48.6K	$12.84	−$624.0K	−1.2%3.96M after	3 lots
Oct 1, 2021 (view filing)	Sep 28-Oct 1	3 daysLate	Simard JohnChief Executive Officer	SSale	−60.9K	$13.34	−$812.2K	−1.5%4.01M after	4 lots
Sep 28, 2021 (view filing)	Sep 23-27	5 daysLate	Simard JohnChief Executive Officer	SSale	−51.2K	$14.71	−$753.3K	−1.2%4.07M after	3 lots
Sep 22, 2021 (view filing)	Sep 20-22	2 days	Simard JohnChief Executive Officer	SSale	−50.0K	$15.15	−$757.6K	−1.2%4.12M after	3 lots
Jul 19, 2021 (view filing)	Jul 14	5 daysLate	Simard JohnChief Executive Officer	SSale	−50.0K	$18.15	−$907.5K	−1.2%4.17M after

Top 10 13F holders, Q2 2026

See all 36 holders

The largest institutional positions in XBiotech Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding XBIT in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
BlackRock, Inc.	321,146	$738.6K	0.00%	+28,042+9.6%	Added
Geode Capital Management, LLC	214,116	$492.8K	0.00%	−16,904−7.3%	Reduced
Vanguard Capital Management LLC	200,182	$460.4K	0.00%	−789−0.4%	Reduced
RBF Capital, LLC	198,501	$456.6K	0.02%	00.0%	Unchanged
Morgan Stanley	147,880	$340.1K	0.00%	−17,674−10.7%	Reduced
Bridgeway Capital Management, LLC	98,447	$226.4K	0.00%	00.0%	Unchanged
Vanguard Fiduciary Trust Co	92,365	$212.4K	0.00%	+789+0.9%	Added
Millennium Management LLC	79,330	$182.5K	0.00%	−26,210−24.8%	Reduced
State Street Corp	73,006	$167.9K	0.00%	00.0%	Unchanged
Northern Trust Corp	66,258	$152.4K	0.00%	−9,829−12.9%	Reduced

Holders of 5% or more of XBIT

See all 2 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of XBiotech Inc..

Largest holders of XBIT from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
Simard John	13G/A	17.70%5.72M shares	−2.20 ppfrom 19.90%	Feb 16, 20225 filings	Jan 23, 2026	SEC
McKenzie W Thorpe	13G/A	9.76%3.01M shares	+0.05 ppfrom 9.71%	Feb 16, 20225 filings	Jan 23, 2026	SEC